Wagner S. Brum

Aug 22, 2024 | medrxiv.org | Nicholas Ashton |Ashvini Keshavan |Wagner S. Brum |Ulf Andreasson

All biomarker measurements were performed by the assay developers in-house without cost. ALZpath p-tau217 was performed at the University of Gothenburg (UGOT) and Lilly immunoassays were performed at the University of Lund. C2N Diagnostics declined to participate in the study. N.J.A. has given lectures in symposia sponsored by Eli-Lilly, Roche Diagnostics, and Quanterix. NJA has declined paid opportunities from ALZpath. A.K. has no conflicts of interest. W.S.B. has no conflicts of interest.

Mar 13, 2024 | nature.com | Wagner S. Brum |Joseph Therriault |Eduardo Zimmer |Sebastian Palmqvist |Henrik Zetterberg |Kaj Blennow | +1 more

AbstractBlood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in memory clinic patients with subjective cognitive decline, mild cognitive impairment or dementia, in the Swedish BioFINDER-2 study (n = 548) and in the TRIAD study (n = 179).

Feb 15, 2024 | psiquiatria.com | Nicholas Ashton |Wagner S. Brum

La tau fosforilada (p-tau) es un biomarcador sanguíneo específico para la patología de la enfermedad de Alzheimer (EA), y se considera que p-tau217 tiene la mayor utilidad. Sin embargo, la disponibilidad de pruebas de p-tau217 para investigación y uso clínico ha sido limitada. Ampliar el acceso a este biomarcador de EA de alta precisión es crucial para una evaluación e implementación más amplias de los análisis de sangre de la EA.

Dec 18, 2023 | jamanetwork.com | Wagner S. Brum |Sahlgrenska Academy |Porto Alegre |Kieran F. Docherty

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial Amyloid-β (Aβ) accumulation is critical in Alzheimer disease (AD), and neprilysin is involved in physiologically clearing Aβ. Concerns exist regarding long-term use of sacubitril/valsartan, a neprilysin inhibitor and angiotensin receptor blocker used for heart failure, and its potential to increase AD risk.

Nov 20, 2023 | alz-journals.onlinelibrary.wiley.com | Wagner S. Brum |Nicholas Ashton |Joel Simrén

1 BACKGROUND Novel technologies to measure brain pathophysiological processes in the blood have revolutionized the Alzheimer's disease (AD) research landscape.1, 2 Established and highly accurate methods for tracking such processes face barriers to their large-scale implementation, such as the high costs, radiation exposure, and limited availability of positron emission tomography (PET) scans, as well as the relative invasiveness of lumbar punctures, required for measuring AD biomarkers in...